SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
DYAX: Dyax Corp.
An SI Board Since November 2000
Posts SubjectMarks Bans Symbol
197 20 0 DYAX
Emcee:  SI (no user) Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
122"We, as well as our commercialization partner, Genzyme are fully committed scaram(o)uche-5/16/2006
121Dyax Provides Update on Regulatory Pathway for DX-88 Monday May 15, 4:02 pm ET Pnigel bates-5/16/2006
120Jerini Appoints Andrew D. Curtis as Vice President U.S. Marketing for Jerini U.Snigel bates-5/2/2006
119yax Files Shelf Registration Statement Monday April 17, 7:30 am ET CAMBRIDGE, Mnigel bates-4/17/2006
118Study Shows Individual Replacement Therapy With C1-Inhibitor Concentrate Reducesnigel bates-3/6/2006
117Positive Topline Results from Phase II Trial (EDEMA2) with DX-88 for the Treatmenigel bates-3/6/2006
116Jerini AG Presents Clinical Development Update for Icatibant in the Treatment ofnigel bates-3/6/2006
115Guffaw! Ugh.scaram(o)uche-1/31/2006
114Not from the lawyer POV...nigel bates-1/31/2006
113a $B market, gone poof.scaram(o)uche-1/31/2006
112<i>The lawyers just noticed...</i> Parker & Waichman, LLP Evalunigel bates-1/31/2006
111medicalnewstoday.com Heart Surgery Drug Raises Kidney Failure Risk Category: Cascaram(o)uche-1/26/2006
110Dyax Corp. Issued Fifth U.S. Patent in Its Phage Display Patent Portfolio Tuesdanigel bates-1/10/2006
109Dyax Corp. and Debiopharm S.A. Restructure Development Agreement for DX-890 (Depnigel bates-12/20/2005
108Dyax and Genzyme Initiate Pivotal Phase III Trial of Subcutaneously Administerednigel bates-12/8/2005
107The just-announced KOSP-Jerini deal in HAE is apt to be the story for DYAX todayDewDiligence_on_SI-11/7/2005
106Dyax Announces Positive Final Results from Phase I Trial of Subcutaneous DX-88 Mnigel bates-11/7/2005
105Dyax Announces Cancer Lead at Drug Discovery Conference Thursday August 11, 7:30scaram(o)uche-8/11/2005
104Dyax Announces Results from Two Clinical Trials of DX-88 Thursday June 30, 7:30 nigel bates-6/30/2005
103Dyax Announces Sale of Common Stock Thursday May 19, 2:36 pm ET CAMBRIDGE, Masnigel bates-5/20/2005
102A Direct Role for C1 Inhibitor in Regulation of Leukocyte Adhesion 1 Shenghe Cakeokalani'nui-5/5/2005
101DX-88 Trials in Hereditary Angioedema To Be Featured at 4th European C1-INH Definigel bates-4/29/2005
100Dyax Corp. Announces First Quarter Financial Results Wednesday April 27, 7:30 amnigel bates-4/27/2005
99Nat Biotechnol. 2005 Feb 20; [Epub ahead of print] Generation of high-affinitynigel bates-2/23/2005
98Can't blame the guy right now... finance.yahoo.com Bought a few more todaynigel bates-2/22/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News